A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients

Sophie C. J. Bosma*, Marlous Hoogstraat, Erik van Werkhoven, Michiel de Maaker, Femke van der Leij, Paula H. M. Elkhuizen, Alain Fourquet, Philip Poortmans, Liesbeth J. Boersma, Harry Bartelink, Marc J. van de Vijver, Young Boost Trial research group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)


Purpose: To investigate risk factors for local recurrence (LR) after breast conserving therapy in young breast cancer patients randomized in the "Young Boost Trial".

Material & methods: In the "Young Boost Trial" 2421 patients

Results: The cumulative 5-year LR rate was 1.07% (95% CI 0.72-1.59%) and 10-year LR rate 2.56% (1.81-3.62%). Analysis of a subset of primary tumors and local recurrences showed similar histopathological characteristics (n = 15), copy number (n = 13) and gene expression profiles (n = 14). Basal subtype was strongly associated with LR in univariable and multivariable analysis. Gains of CCND1 were identified more frequently among controls, while more frequent gains of FGFR1 and IGF1R were observed among cases. Upregulation of genes involved in the p53-pathway was observed in recurring tumors compared to non-recurring tumors. We could not identify a genomic classifier for LR.

Conclusions: All investigated local recurrences were true genomic recurrences. Although differences in copy number variation and gene expression pathways were observed in recurring tumors compared to non-recurring tumors, no genomic classifier for LR could be identified. (C) 2020 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)127-135
Number of pages9
JournalRadiotherapy and Oncology
Publication statusPublished - Mar 2021


  • Early-stage breast cancer
  • Breast conserving therapy
  • Local control

Cite this